- Home
- BRAG vs CUE Comparison
BRAG vs CUE Comparison
Compare BRAG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRAG | CUE |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 233.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BRAG | CUE |
|---|---|---|
| Price | $1.36 | $28.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.00 | ★ $120.00 |
| AVG Volume (30 Days) | 24.4K | ★ 359.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.25 | $0.17 |
| 52 Week High | $3.20 | $45.50 |
Technical Indicators
Market Signals| Indicator | BRAG | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 40.05 | 48.30 |
| Support Level | $1.25 | $23.51 |
| Resistance Level | $1.82 | $33.11 |
| Average True Range (ATR) | 0.09 | 4.75 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 30.77 | 31.98 |
Price Performance
Historical ComparisonAbout BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic, and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from Malta, and the rest from Netherlands, Curacao, the United States, Croatia, Marshall Islands, Brazil, Isle of Man, Belgium, Czech Republic, and other regions.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.